Suppr超能文献

长链非编码RNA MALAT1通过抑制miR-155表达和激活FBXW7功能在胶质瘤细胞中发挥肿瘤抑制作用。

Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function.

作者信息

Cao Shuanzhu, Wang Yanzhou, Li Jinquan, Lv Mingliang, Niu Haitao, Tian Yong

机构信息

Department of The Fourth Neurosurgery, Central Hospital Cangzhou City Cangzhou 061000, Hebei Province, China.

Department of Neurosurgery, Botou Hospital Cangzhou 061000, Hebei Province, China.

出版信息

Am J Cancer Res. 2016 Nov 1;6(11):2561-2574. eCollection 2016.

Abstract

The human metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is a long non-coding RNA associated with metastasis, and is a favorable prognostic factor for lung cancer. Recent studies have shown that MALAT1 plays an important role in many malignancies. However, little is known about the role of MALAT1 in glioma. In this study, we determined the expression of MALAT1 and explored its prognostic value in glioma. Further, we investigated the regulatory mechanism of MALAT1 in glioma progression. Our results showed that the expression of MALAT1 was significantly decreased in glioma specimens than in noncancerous brain tissues. In addition, MALAT1 expression was significantly correlated with tumor size, WHO grade and Karnofsky Performance Status (KPS), and was an independent prognostic factor for survival of glioma patients. The gain- and loss-of-function experiments revealed miR-155 down-regulation by MALAT1, resulting in reciprocal effects. Further, MALAT1 suppresses cell viability by down-regulating miR-155. FBXW7 mRNA was identified as a direct target of miR-155 in glioma. The miR-155-induced tumorigenesis is mediated through FBXW7 function. Finally, we found that MALAT1 positively regulated FBXW7 expression, which was responsible for glioma progression mediated by MALAT1-miR-155 pathway. In conclusion, our data demonstrated that MALAT1 may be a novel prognostic biomarker and therapeutic target in glioma. Restoration of MALAT1 levels represents a novel therapeutic strategy against glioma.

摘要

人类转移相关肺腺癌转录本1(MALAT1)是一种与转移相关的长链非编码RNA,是肺癌的一个良好预后因素。最近的研究表明,MALAT1在许多恶性肿瘤中发挥着重要作用。然而,关于MALAT1在胶质瘤中的作用知之甚少。在本研究中,我们测定了MALAT1的表达,并探讨了其在胶质瘤中的预后价值。此外,我们研究了MALAT1在胶质瘤进展中的调控机制。我们的结果表明,与非癌脑组织相比,胶质瘤标本中MALAT1的表达显著降低。此外,MALAT1表达与肿瘤大小、世界卫生组织(WHO)分级和卡诺夫斯基功能状态(KPS)显著相关,是胶质瘤患者生存的独立预后因素。功能获得和缺失实验表明,MALAT1下调miR-155,产生相互作用。此外,MALAT1通过下调miR-155抑制细胞活力。FBXW7 mRNA被确定为胶质瘤中miR-155的直接靶点。miR-155诱导的肿瘤发生是通过FBXW7功能介导的。最后,我们发现MALAT1正向调节FBXW7表达,这是由MALAT1-miR-155途径介导的胶质瘤进展的原因。总之,我们的数据表明,MALAT1可能是胶质瘤中的一种新型预后生物标志物和治疗靶点。恢复MALAT1水平代表了一种针对胶质瘤的新型治疗策略。

相似文献

3
Long noncoding RNA MALAT1 promotes cell proliferation through suppressing miR-205 and promoting SMAD4 expression in osteosarcoma.
Oncotarget. 2017 Sep 6;8(63):106648-106660. doi: 10.18632/oncotarget.20678. eCollection 2017 Dec 5.
4
Knockdown of long non-coding RNA MALAT1 increases the blood-tumor barrier permeability by up-regulating miR-140.
Biochim Biophys Acta. 2016 Feb;1859(2):324-38. doi: 10.1016/j.bbagrm.2015.11.008. Epub 2015 Nov 24.
7
Malat1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STMN1, RAB5A and ATG4D expression in glioma.
Biochem Biophys Res Commun. 2017 Oct 21;492(3):480-486. doi: 10.1016/j.bbrc.2017.08.070. Epub 2017 Aug 20.
8
Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma.
Tumour Biol. 2015 May;36(5):3355-9. doi: 10.1007/s13277-014-2969-7. Epub 2015 Jan 23.
10
Blocking lncRNA MALAT1/miR-199a/ZHX1 Axis Inhibits Glioblastoma Proliferation and Progression.
Mol Ther Nucleic Acids. 2019 Dec 6;18:388-399. doi: 10.1016/j.omtn.2019.09.005. Epub 2019 Sep 17.

引用本文的文献

1
F-box proteins at the crossroads of ubiquitination and tumor immunity: regulatory networks and immunotherapy strategies.
Front Immunol. 2025 Jun 4;16:1596344. doi: 10.3389/fimmu.2025.1596344. eCollection 2025.
3
Combined Effect of Conventional Chemotherapy with Epigenetic Modulators on Glioblastoma.
Genes (Basel). 2025 Jan 24;16(2):138. doi: 10.3390/genes16020138.
4
Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application.
Cancers (Basel). 2025 Feb 8;17(4):579. doi: 10.3390/cancers17040579.
5
LncRNA MKLN1-AS promotes glioma tumorigenesis and growth via activating the Hippo pathway through miR-126-5p/TEAD1 axis.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec 16. doi: 10.1007/s00210-024-03646-y.
7
Molecular insights and clinical implications for the tumor suppressor role of SCF E3 ubiquitin ligase.
Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189140. doi: 10.1016/j.bbcan.2024.189140. Epub 2024 Jun 21.
8
Expression of lncRNAs in glioma: A lighthouse for patients with glioma.
Heliyon. 2024 Jan 24;10(3):e24799. doi: 10.1016/j.heliyon.2024.e24799. eCollection 2024 Feb 15.
9
Lnc-PTCHD4-AS inhibits gastric cancer through MSH2-MSH6 dimerization and ATM-p53-p21 activation.
Aging (Albany NY). 2023 Nov 27;15(22):13558-13578. doi: 10.18632/aging.205329.

本文引用的文献

1
Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Oncotarget. 2016 Aug 16;7(33):52751-52765. doi: 10.18632/oncotarget.10481.
4
miR-155-SOCS1 as a Functional Axis: Satisfying the Burden of Proof.
Immunity. 2015 Jul 21;43(1):3-4. doi: 10.1016/j.immuni.2015.06.020.
5
Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway.
Int J Oncol. 2015 Jul;47(1):231-43. doi: 10.3892/ijo.2015.2981. Epub 2015 May 4.
6
Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma.
Tumour Biol. 2015 May;36(5):3355-9. doi: 10.1007/s13277-014-2969-7. Epub 2015 Jan 23.
8
An emerging understanding of long noncoding RNAs in kidney cancer.
J Cancer Res Clin Oncol. 2014 Dec;140(12):1989-95. doi: 10.1007/s00432-014-1699-y. Epub 2014 May 11.
10
The multilayered complexity of ceRNA crosstalk and competition.
Nature. 2014 Jan 16;505(7483):344-52. doi: 10.1038/nature12986.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验